Spain A roundup of the latest news from Spanish pharma, including Almirall’s earnings forecast for 2023; stock price rise and layoffs at Grifols; PharmaMar’s first European approval for its lurbinectedin treatment of metastatic Small Cell Lung Cancer and Esteve’s launch of the first inhaled rescue treatment for Parkinson’s patients. Spain’s…
Roundup A roundup of the latest news from Spanish pharma, including J&J’s COVID-19 vaccine trial, the latest developments at Spanish firm PharmaMar which hopes its Aplidin can be used as a treatment for COVID-19, and a new biologics plant for contract manufacturer LSNE in the city of León. Johnson &…
Spain PharmaMar, a Spanish firm, is beginning Phase II clinical trials for its anti-tumour drug Aplidin to treat coronavirus. The firm’s stocks have soared on the news. PharmaMar is joining the race to find a treatment for COVID1-9. The Madrid-based company that developed multiple myeloma therapy Aplidin (plitidepsin) announced that…
Austria Mario Huber, general manager of PharmaMar Austria, a multinational and an innovative oncology-based Spanish company, discusses the growth of the company in Austria and the reasons behind the success of Yondelis®, the company’s flagship product. Furthermore, he provides an overview of the clinical trials the Austrian affiliate is undertaking and…
Austria Like a family recipe that has been refined and perfected over countless generations, Austria has developed a reputation as the quintessential clinical trials destination; a perfect combination of world-class academia, willing volunteers and educated medical personnel balanced against a backdrop of economic stability. “Austria should be proud of the abundance…
See our Cookie Privacy Policy Here